Realgar-Indigo Naturalis Formulation
Arsenic Trioxide
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Arsenic Trioxide cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cedazuridine The University of Hong Kong | Phase 2 | CCC |
Venetoclax The University of Hong Kong | Phase 2 | CCC |
Azacitidine The University of Hong Kong | Phase 2 | CCC |
Decitabine The University of Hong Kong | Phase 2 | CCC |
Arsenic Trioxide The University of Hong Kong | Phase 2 | CCC |
Same molecule, other indications
Realgar-Indigo Naturalis Formulation is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →